Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia

Kayseri Education and Research Hospital

Status and phase: Completed; Phase 4

Conditions: Apoptotic Signal Pathways in Endometrial Hyperplasia

Treatments: Drug: Metformin; Drug: medroxyprogesterone acetate; Drug: 17β estradiol hemihydrate

Study type: Interventional

Funder types: Other

Identifiers

NCT02872818

14/128

Details and patient eligibility

About

The purpose of the study is to determine apoptotic signaling pathways such as Survivin, Bcl-2, Bax, c-Myc and caspase-9 expression levels in rats model with iatrogenic endometrial hyperplasia after metformin and medroxyprogesterone acetate administration.

Enrollment: 40 patients

Sex: Female

Ages: 8 to 10 weeks old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:

Forty-eight weeks old female Wistar-Albino rats, weighting between 180 and 260 g

Exclusion criteria.

We have no exclusion criteria because we examine drugs effects in the experimental rats

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

40 participants in 3 patient groups

Control group

Active Comparator group

Description:

Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia

Treatment:

Drug: 17β estradiol hemihydrate

Metformin group

Active Comparator group

Description:

Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days

Treatment:

Drug: 17β estradiol hemihydrate

Drug: Metformin

Medroxyprogesterone acetate group

Active Comparator group

Description:

Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days

Treatment:

Drug: 17β estradiol hemihydrate

Drug: medroxyprogesterone acetate